Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb trial of a high-dose, continuous delivery formulation of subcutaneously administered levodopa/carbidopa (ND0612H) in patients with Parkinson's disease.

Next Previous
Trial Profile

Phase IIb trial of a high-dose, continuous delivery formulation of subcutaneously administered levodopa/carbidopa (ND0612H) in patients with Parkinson's disease.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors NeuroDerm

    • Most Recent Events

    • 23 Nov 2015 Planned initiation date changed from 1 Jul 2015 to 1 Dec 2015.
    • 12 Nov 2015 According to the media release of NeuroDerm Ltd., this trial will be initiated by the end of 2015 or in the beginning of 2016.
    • 12 Nov 2015 According to the media release of NeuroDerm Ltd., the company has incorporated the written feedback received from U.S. Food and Drug Administration (FDA). Also, this trial will be conducted at centers in Israel, E.U and U.S.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top